【摘要】 目的探讨艾司西酞普兰合并齐拉西酮治疗难治性抑郁症的疗效与不良反应。方法将58例难治性抑郁症分为艾司西酞普兰合并齐拉西酮29例为研究组,单用艾司西酞普兰29例为对照组,采用汉密尔顿抑郁量表(HAMD-17)评定疗效,并观察用药过程中的不良反应,疗程8周。结果研究组有效率为79.31%,对照组为55.17%,差异有统计学意义(χ2=3.84,P<0.05);治疗结束后,两组HAMD评分均显著降低,以研究组疗效较好而快(P<0.01),两组不良反应差异无统计学意义(P>0.05)。结论艾司西酞普兰合并齐拉西酮治疗难治性抑郁症疗效优于单用艾司西酞普兰,且起效快,不增加不良的反应。更多还原

【Abstract】 [Objective]To investigate the efficacy and adverse reactions of ziprasidone combined with escitalopram in the treatment of refractory depression.[Methods]A total of 58 patients with refractory depression were divided into study group(29 cases) and control group(29 cases).Study group received escitalopram and ziprasidone administration,and the control group with escitalopram alone for 8 weeks.Hamilton depressive scale(HAMD-17) and treatment emergent symptom scale(TESS) were used to evaluate the efficacy and adverse effects.[Results] The effective rate in study group and control group was 79.31% and 55.17%,respectively,with significant difference(χ2=3.84,P<0.05).After treatment,the scores of HAMD in 2 groups were descended,the study group was better than the control group in the efficacy(P<0.01),the adverse effect was not significant different between 2 groups(P>0.05).[Conclusion]The efficacy of combined ziprasidone and escitalopram is better than ziprasidone alone,with characteristics of rapid effect and no more adverse effect.更多还原